NCT07587827 — Centre Georges Francois Leclerc cancer vaccine trial
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer
Registry record
| Registry ID | NCT07587827 ↗ |
|---|---|
| Lead sponsor | Centre Georges Francois Leclerc |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Not Yet Recruiting |
| Indication | Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Cancer |
| Enrollment | 77 participants (target) |
| Start date | 2026-11-01 |
| Primary completion | 2027-05-01 (est.) |
| Last registry update | 14 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07587827), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07587827?
NCT07587827 (Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer) is registered on ClinicalTrials.gov as Phase 1, sponsored by Centre Georges Francois Leclerc.
Is NCT07587827 recruiting?
As of the 2026-05-14 registry update, NCT07587827 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07587827?
The lead sponsor is Centre Georges Francois Leclerc.
What condition does NCT07587827 study?
The registered conditions are Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Cancer. Primary completion is listed as 2027-05-01 (estimated).
Are results available for NCT07587827?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07587827.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.